A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to estimate the time to progressive disease for
patients with advanced hepatocellular cancer who receive LY2181308.